Navigation Links
Pevion's Therapeutic Candida Vaccine Shows Robust Systemic and Mucosal Immunogenicity, While Epidemiological Survey Confirms Excellent Market Potential
Date:10/11/2011

BERN, Switzerland, October 11, 2011 /PRNewswire/ --

Pevion Biotech AG today announced latest results from the ongoing clinical study of its therapeutic Candida vaccine PEV7, showing high levels of specific antibodies and a 100% mucosal immune response rate. The announcement further included the results of the largest, international representative epidemiological survey to date on recurrent vulvovaginal candidiasis (RVVC), confirming that 7% of adult women suffer from the disease.

The newly announced data come from the group of volunteers vaccinated with the intramuscular high dose of PEV7 and showed significantly increased immunogenicity over the previously vaccinated low-dose group, while confirming the excellent safety profile customary for virosome-delivered vaccines. Particularly relevant for the postulated mode-of-action of PEV7 was the strong immune response detected in vaginal and cervical samples. All volunteers showed a mucosal immune response with consistently high titers across the group.

"An immune response of this magnitude in the cervicovaginal compartment is very encouraging with regards to the therapeutic potential of the vaccine," stated Jean-Paul Prieels, former Head of Vaccine R&D at GlaxoSmithKline and recently elected  Board Member at Pevion. "After seeing the first positive immunogenicity data from the low dose group, we defined criteria on what immunogenicity outcome we would regard as best case for the high dose. We are delighted that these criteria have been met in full. We are now following the level of immune response over time and see first promising signs in terms of mucosal antibody persistence."

In order to further validate the disease burden and the commercial potential of PEV7, Pevion mandated the largest, international representative epidemiological survey on RVVC among 6'000 women, generating robust data on prevalence, incidence and the age structure of the RVVC patient population. The study
'/>"/>

SOURCE Pevion Biotech AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
2. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
3. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
4. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
5. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
6. ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development
7. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
8. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
9. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
10. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
11. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015 Sinovac Biotech Ltd. (Nasdaq: SVA), ... announced its unaudited financial results for the fourth quarter ... Fourth Quarter 2014 Financial Highlights(Compared to the fourth quarter ... a decrease of 11.4% from $22.9 million in the ... of H5N1 pandemic influenza vaccine of $0.1 million in ...
(Date:4/18/2015)... 18, 2015 Aurigene and ... will be presenting data at the poster sessions ... Cancer Research Annual Meeting (April 18-22 in ... (Logo: http://photos.prnewswire.com/prnh/20130418/608115 ) , Aurigene ... (NAMPT) small molecule inhibitors program, which is currently ...
(Date:4/17/2015)... TORONTO , April 17, 2015 /PRNewswire/ - SQI ... sciences and diagnostics company that develops and commercializes ... ("SQI"), today announced that it has received approval ... expiry of 5,126,044 outstanding common share purchase warrants ... in connection with the Company,s May 2013 private ...
(Date:4/17/2015)... LC Sciences LLC, a leading ... that it is seeking beta testers for the ... based targeted sequencing technology. The system offers cost-effective, ... accurate detection of rare variants. It utilizes novel ... company will collaborate with beta testers to generate ...
Breaking Biology Technology:Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3
... , , ... The skill of culturing mammalian cells ... Cell counts must be taken daily, a task that is ... error because of operator subjectivity. To that end, a simple ...
... , New Advances in Scanner Design ... , ... Affymetrix GeneChip Scanner 3000 design lays the foundation for ... genetic analysis system, supporting continued feature size reduction for higher resolution ...
... Tunable Parameters of the Affymetrix Expression ... Introduction , The Statistical ... set data to generate expression values (Signals and LogRatios), Detection and ... array. , Non-parametric rank tests ...
Cached Biology Technology:Improving the accuracy and speed of mammalian cell counting 2Improving the accuracy and speed of mammalian cell counting 3Improving the accuracy and speed of mammalian cell counting 4Improving the accuracy and speed of mammalian cell counting 5The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 2The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 3The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 4The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 5The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 6The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 7The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 8The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 9The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 10Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 2Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 3Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 4Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 5Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 6Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 7Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 8Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 9Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 10
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
(Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2
... have discovered a new cause for thyroid hormone deficiency, ... by problems of the thyroid gland, and more rarely, ... (hypophysis). However, a new cause of the disease has ... in the journal Nature Genetics . The scientists, ...
... international team of scientists working at the Plasma Technology ... the first time the absolute density of active substances ... as plasma, in a study about to be published ... for medicinefor example, for stimulating tissue regeneration, or to ...
... and "sea" for many will invoke associations of reserves, business, ... the efforts in Israel,s energy field are being directed at ... geophysical study, the first of its kind in Israel, has ... Bay seabed, at relatively shallow depths, only a few dozen ...
Cached Biology News:New cause of thyroid hormone deficiency discovered 2New cause of thyroid hormone deficiency discovered 3Undersea gas leaks off Israel's coast are discovered by University of Haifa researchers 2
Features , Designed to assist users in applying domed caps to tube strips and plates , Minimises the pressure required to seal the caps effectively , Enables multiple tubes to be sealed simultaneousl...
Lysozyme C (W-20)...
... The Jouan B4i ventilated and BR4i refrigerated ... and low speed operation at a low sound ... accessories certified for biocontainment. Their AUTO-LOCK rotor exchange ... is ready for use within seconds. ...
... X-Gal (5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside) is ... to identify recombinant plasmids. ... X-Gal and IPTG, ... appear blue, whereas recombinant ...
Biology Products: